Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing for a June launch of AUVELITY in Alzheimer’s disease agitation while continuing to expand its push in major depressive disorder, citing broad payer access, a larger sales force and what they described as a differentiated clin
Mobile Infrastructure (NASDAQ:BEEP) reported first-quarter 2026 results that management said reflected progress on utilization, contract growth and asset sales, while reaffirming its full-year outlook.
Chief Executive Officer Stephanie Hogue said the company’s first-quarter performance showed “soli
Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself amid a legal dispute with distribution partner NS Pharma and parent company Nippon Shinyaku.
On t
DoubleDown Interactive (NASDAQ:DDI) reported higher first-quarter revenue and profit, with management pointing to growth from acquired businesses, a larger direct-to-consumer revenue mix in social casino and continued cash generation across the company.
For the quarter ended March 31, 2026, the com
Arteris (NASDAQ:AIP) reported record first-quarter results for 2026, with management pointing to strong demand tied to artificial intelligence chips, data center infrastructure, automotive systems and cybersecurity as key drivers of growth.
Chief Executive Officer K. Charles Janac said the quarter
Astronics (NASDAQ:ATRO) raised its full-year 2026 revenue outlook after reporting a stronger first quarter marked by record bookings and backlog, higher margins and broad demand across its aerospace and test systems businesses.
Chairman, President and CEO Peter Gunderman said the company viewed the
Atea Pharmaceuticals (NASDAQ:AVIR) said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no approved treatment options.
During the company’s first-quarter 2026 earnings call, Chief Executive Off
Jenoptik (ETR:JEN) reported record first-quarter order intake for 2026, driven by a sharp rebound in semiconductor-related demand and stronger biophotonics activity, while revenue was slightly lower year over year and profitability improved.
President and CEO Stefan Traeger told analysts that order
